Sep 24, 2024 · Discover Takeda Oncology's decades of leadership in oncology. Explore their approach, latest news, pipeline, and innovative therapies.

Mar 3, 2025 · Explore efficacy and safety results from the Phase 3 VERIFY study evaluating Protagonist and Takeda's rusfertide in patients with polycythemia vera.

Learn about Takeda Oncology's mission to cure cancer through patient inspiration and innovation. Discover their leadership in oncology, diverse pipeline, and commitment to improving patient access to innovative medicines.

Learn about Mohamed Samir, M.D., Head of Global Medical Affairs Oncology at Takeda. Discover his extensive experience in clinical research and development and medical affairs across multiple therapeutic areas.

Takeda Oncology has a patient-first mindset, committed to helping people living with cancer navigate their journey. Learn about how Oncologt Patient Advocacy and Engagement works to uncover and address the unmet needs of people living with cancer.

Takeda Pharmaceutical Company Limited today announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIG™ (brigatinib) in patients with crizotinib-refractory anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) were published ...

(NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) were published in the journal Blood. The manuscript, which summarizes the five-year, end-of-study results ...

May 14, 2024 · Building on decades of leadership in oncology, we are focused on providing approved medicines for patients in need and advancing a cutting-edge oncology pipeline with the potential to introduce new therapies for people with solid tumors and hematologic cancers.

Explore our pipeline of investigational therapies for cancer treatment and learn more about the phases of development and indications being studied.

Access media materials, including an overview of Takeda Oncology, leadership biographies, and fact sheets on disease states, inlcuding ALK+ NSCLC and metastatic colorectal cancer (mCRC). Download these resources for comprehensive information on …